NCT00070096已完成2 期
A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Efficacy
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with metastatic germ cell tumors that are refractory to cisplatin.
详细描述
OBJECTIVES:
- Determine the efficacy of ixabepilone in patients with metastatic cisplatin-refractory germ cell tumors.
- Determine the safety of this drug in these patients.
OUTLINE: Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1.3-4 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Efficacy
Safety
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Ixabepilone in Treating Patients With Metastatic Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate CancerNCT00087139National Cancer Institute (NCI)124
已完成
2 期
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial CancerEndometrial AdenocarcinomaRecurrent Endometrial CarcinomaStage IV Endometrial CarcinomaNCT00095979National Cancer Institute (NCI)52
已完成
2 期
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerPeritoneal Cavity CancerOvarian CancerNCT00030706Montefiore Medical Center
终止
1 期
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast CancerBreast CancerNCT00765765University of Medicine and Dentistry of New Jersey6
已完成
2 期
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast CancerBreast CancerNCT00045097National Cancer Institute (NCI)